A Phase III trial to assess efficacy and safety of chemotherapy as an adjuvant treatment for patients with BRCA1/2 Mutations and high risk Her2 negative primary breast cancer

Cancer, Cancer - Breast
Grace Makari-Judson, MD

D’Amour Center for Cancer Care
3350 Main Street
Springfield MA 01199

The purpose of this study is to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation.
Non-metastatic breast cancer; ER/PR negative; HER2 negative; BRCA1 or 2 mutation
Rae Lynn Defeo